Phase II study of rhizoxin in squamous cell head and neck cancer
1996

Study of Rhizoxin in Head and Neck Cancer

Sample size: 32 publication Evidence: low

Author Information

Author(s): J Verweij, J Wanders, Th Gil, P Schoffski, G Catimel, A te Velde, PHM de Mulder

Primary Institution: Rotterdam Cancer Institute

Hypothesis

To test the anti-tumour activity of rhizoxin in recurrent and/or metastatic squamous cell head and neck cancer.

Conclusion

Rhizoxin has minor activity in recurrent and/or metastatic squamous cell head and neck cancer.

Supporting Evidence

  • Two objective partial responses were observed, lasting 7.5 and 3.5 months.
  • Overall response rate regarding evaluable patients is 8%.
  • Severe pain at the tumour site was a notable side effect.

Takeaway

This study looked at a new drug called rhizoxin to see if it helps people with a type of throat cancer, but it didn't work very well.

Methodology

Patients with recurrent or metastatic squamous cell head and neck cancer were treated with rhizoxin and monitored for response and toxicity.

Limitations

The study had a small sample size and only two partial responses were observed.

Participant Demographics

30 males and 2 females, median age 60 (range 31-75).

Statistical Information

Confidence Interval

95% confidence interval 1-26%.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication